Retatrutide vs Survodutide.

Retatrutide (development code LY3437943) is an investigational once-weekly injectable peptide developed by Eli Lilly for the treatment of obesity and related cardiometabolic disease. It is a single synthetic peptide engineered to act as a "triple G" agonist, simultaneously stimulating three nutrient-hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This distinguishes it from the single agonist semaglutide (GLP-1) and the dual agonist tirzepatide (GIP/GLP-1), both already approved.

Survodutide (BI 456906) is an investigational once-weekly injectable peptide that activates two gut-hormone receptors at once: the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). It is being co-developed by Boehringer Ingelheim and Zealand Pharma as a candidate treatment for obesity and for metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH). It is not an approved medicine and is available only within regulated clinical trials. The dual-receptor design is intended to combine appetite and blood-sugar effects with an added push on energy expenditure and liver-fat handling.

Retatrutide is a balanced agonist at three receptors, each contributing a distinct metabolic effect. GLP-1 receptor agonism enhances glucose-dependent insulin secretion, slows gastric emptying, and acts centrally to reduce appetite and food intake. GIP receptor agonism further modulates insulin response and appears to improve nutrient handling and tolerability. The defining addition is glucagon receptor agonism, which raises hepatic glucose output and, importantly, increases energy expenditure and promotes hepatic lipid oxidation/mobilization. The combination is intended to layer glucagon-driven increases in energy expenditure and reductions in liver fat on top of the appetite suppression and glycemic benefits of incretin (GLP-1/GIP) signaling. Because glucagon agonism can raise hepatic glucose production and resting heart rate, the receptor balance and dose are designed to keep net effects metabolically favorable.

As a GLP-1 receptor agonist, survodutide slows gastric emptying, enhances glucose-dependent insulin secretion, and reduces appetite through central pathways. Its distinguishing feature is simultaneous agonism of the glucagon receptor, which in this metabolic context is thought to raise energy expenditure and promote hepatic fat mobilization. This balanced dual agonism aims to produce greater weight loss and liver benefit than GLP-1 activation alone. The molecule is engineered for a long half-life to permit weekly subcutaneous dosing.

Human evidence comes from a completed Phase 2 program and emerging Phase 3 data, so this is no longer animal-only, though long-term outcome and safety data remain immature. In the 48-week Phase 2 obesity trial (Jastreboff et al., NEJM 2023), adults with obesity/overweight without diabetes had least-squares mean weight reductions of roughly -17.1%, -22.8%, and -24.2% across higher dose groups versus -2.1% with placebo. A parallel Phase 2 trial in type 2 diabetes (Rosenstock et al., Lancet 2023) showed substantial reductions in HbA1c and body weight. A Phase 2a trial in metabolic dysfunction-associated steatotic liver disease (Nature Medicine 2024) reported large relative reductions in liver fat, with the majority of higher-dose participants reaching liver fat below the steatosis threshold. In May 2026 Lilly reported topline Phase 3 results (TRIUMPH-1, ~2,339 adults), with the highest dose producing about 28.3% mean weight loss at 80 weeks; full peer-reviewed Phase 3 publications and the broader TRIUMPH cardiovascular/diabetes outcome trials were still pending at that time.

The core efficacy dataset for survodutide comes from a randomised, double-blind, placebo-controlled, dose-finding Phase 2 trial published in The Lancet Diabetes & Endocrinology (2024) and sponsored by Boehringer Ingelheim, in which 386 adults with obesity received survodutide (0.6-4.8 mg) or placebo over 46 weeks. Mean body-weight reductions were roughly -6.2%, -12.5%, -13.2% and -14.9% across ascending doses versus -2.8% for placebo under the treatment-policy analysis, with weight loss of nearly 19% among participants who reached and stayed on the highest dose. Weight loss was dose-dependent and had not clearly plateaued by week 46, suggesting further potential with longer treatment. The design limits interpretation: a single dose-finding study, placebo rather than active comparator, a 46 week horizon, and body weight as a surrogate rather than a clinical outcome. Survodutide has also been studied in a Phase 2 MASH trial, where it improved liver histology endpoints relative to placebo, and a later mediation analysis published in Hepatology examined how much of the liver benefit tracked with weight reduction and how much appeared independent of it. Larger Phase 3 obesity and MASH programs are underway to confirm efficacy and long-term safety; results reported so far include a Phase 3 trial of once-weekly survodutide in adults with obesity in the New England Journal of Medicine and the SYNCHRONIZE-MASLD Phase 3 trial in adults with obesity and metabolic dysfunction-associated steatotic liver disease in Nature Medicine. Several gaps remain explicit. There is no dedicated cardiovascular outcome trial result for survodutide, unlike semaglutide, which has published cardiovascular outcome data. There are no head-to-head randomised comparisons against semaglutide or tirzepatide, both of which have completed registrational programs and regulatory approval, so cross-trial percentage comparisons are not reliable. There is no multi-year durability, weight-regain, or paediatric evidence. As an investigational agent, its benefit-risk profile is not yet established.

In trials the most common adverse events were gastrointestinal (nausea, vomiting, diarrhea, constipation), dose-related, mostly mild to moderate, and concentrated during dose escalation; using a lower starting dose partially mitigated them. A mechanistically important signal is a dose-dependent increase in heart rate, which in the Phase 2 obesity trial peaked around 24 weeks before declining; glucagon receptor agonism also raises hepatic glucose output, requiring monitoring. Phase 3 topline data showed dose-dependent discontinuation due to adverse events. Because retatrutide is investigational, its long-term safety, cardiovascular outcomes, and effects in broad real-world populations are not yet established. Compounded, "research-use-only," or gray-market retatrutide is not quality-controlled and carries additional, unquantified risks.

In the Phase 2 obesity trial, adverse events were common and predominantly gastrointestinal, including nausea, vomiting and diarrhoea, occurring far more often than with placebo. These effects were most frequent during dose escalation, consistent with the GLP-1 drug class. A slower titration schedule was explored to improve tolerability. Beyond the trial data, the incretin class carries recognised issues that a regulator will expect to see characterised: gallbladder and biliary events, reported cases of pancreatitis, retained gastric contents relevant to sedation and anaesthesia, loss of lean mass alongside fat mass, and rodent thyroid C-cell findings that have shaped labelling for several agents. Glucagon receptor agonism adds its own questions, notably heart rate increases and hepatic parameters, which is why trials of this class typically require scheduled liver chemistry, heart rate and blood pressure monitoring, contraception and pregnancy exclusion, and structured stopping rules for intolerable gastrointestinal effects. Because survodutide is still in trials, rare or long-term risks remain incompletely characterized, and it should only be used under clinical-trial supervision. There is also a supply problem outside that setting: survodutide is not commercially manufactured for patients, so any material offered through grey-market research-chemical channels has no verified identity, potency, purity or sterility, no cold-chain guarantee, and no adverse-event reporting pathway. Contamination and mislabelling in that supply chain are documented concerns for peptides generally, and they compound the fact that the underlying molecule has no established safety profile in unsupervised use.

As of mid-2026 retatrutide is investigational and not approved by the FDA, EMA, MHRA, or any other regulator for any indication; it remains in Phase 3 development (the TRIUMPH program) by Eli Lilly. It is not a dietary supplement and any product sold as "research-use-only" retatrutide is unapproved.

Survodutide is an investigational drug and has not been approved by the FDA, EMA, or any major regulator for any indication. It carries an FDA Breakthrough Therapy designation for MASH with fibrosis. Any use outside a registered clinical trial is unapproved.